Brought to you by 
Spectrum pays $195mm in cash, plus CVRs, to buy Allos
06 Sep 2012
Executive Summary
Spectrum Pharmaceuticals Inc. (therapies for solid tumors and blood cancers) will pay $1.82 per share (a 23% premium; about $195mm) to buy fellow oncology company Allos Therapeutics Inc. The acquisition also carries with it contingent value rights (CVRs), which will give Allos shareholders an additional $0.11 per share if the company’s sole product Folotyn (pralatrexate) is approved in additional territories.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Spectrum pays $195mm in cash, plus CVRs, to buy Allos
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice